DXB Stock Overview
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Dimerix Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.32 |
52 Week High | AU$0.37 |
52 Week Low | AU$0.052 |
Beta | 0.56 |
1 Month Change | 4.92% |
3 Month Change | 88.24% |
1 Year Change | 229.90% |
3 Year Change | 25.49% |
5 Year Change | 276.47% |
Change since IPO | 60.00% |
Recent News & Updates
Recent updates
Is Dimerix (ASX:DXB) Using Too Much Debt?
Dec 19We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate
Jul 05Can Dimerix (ASX:DXB) Afford To Invest In Growth?
Feb 17We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate
Sep 16We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate
Jun 02Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation
Sep 20Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?
May 17Here's What We Think About Dimerix's (ASX:DXB) CEO Pay
Feb 01Shareholder Returns
DXB | AU Biotechs | AU Market | |
---|---|---|---|
7D | 10.3% | 2.9% | 0.4% |
1Y | 229.9% | -7.5% | 6.0% |
Return vs Industry: DXB exceeded the Australian Biotechs industry which returned -7.5% over the past year.
Return vs Market: DXB exceeded the Australian Market which returned 6% over the past year.
Price Volatility
DXB volatility | |
---|---|
DXB Average Weekly Movement | 16.3% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 8.9% |
10% most volatile stocks in AU Market | 17.6% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: DXB's share price has been volatile over the past 3 months.
Volatility Over Time: DXB's weekly volatility has decreased from 26% to 16% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Nina Webster | dimerix.com |
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.
Dimerix Limited Fundamentals Summary
DXB fundamental statistics | |
---|---|
Market cap | AU$184.12m |
Earnings (TTM) | -AU$10.87m |
Revenue (TTM) | AU$9.12m |
19.3x
P/S Ratio-16.2x
P/E RatioIs DXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DXB income statement (TTM) | |
---|---|
Revenue | AU$9.12m |
Cost of Revenue | AU$0 |
Gross Profit | AU$9.12m |
Other Expenses | AU$19.98m |
Earnings | -AU$10.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.02 |
Gross Margin | 100.00% |
Net Profit Margin | -119.20% |
Debt/Equity Ratio | 83.2% |
How did DXB perform over the long term?
See historical performance and comparison